Madeleine Duvic

List of Publications by Year in Descending Order

352 papers	19,940 citations	73 h-index	133 g-index
363 ext. papers	22,508 ext. citations	4 avg, IF	6.45 L-index

#	Paper	IF	Citations
352	New Practical Aspects of Sweet Syndrome.. *American Journal of Clinical Dermatology*, **2022**, 1	7.1	5
351	Vulvar Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma. *International Journal of Gynecological Pathology*, **2021**, 40, 229-233	3.2	1
350	Teledermatology During COVID-19: An Updated Review. *American Journal of Clinical Dermatology*, **2021**, 22, 467-475	7.1	7
349	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. *European Journal of Cancer*, **2021**, 148, 411-421	7.5	6
348	Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. *American Journal of Hematology*, **2021**, 96, E350-E353	7.1	1
347	Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells. *Cytometry Part B - Clinical Cytometry*, **2021**, 100, 183-191	3.4	8
346	Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 97-105	2	7
345	Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 479, 377-383	5.1	1
344	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. *Blood Advances*, **2021**, 5, 5098-5106	7.8	5
343	Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma during extracorporeal photopheresis. *Photodermatology Photoimmunology and Photomedicine*, **2021**,	2.4	0
342	Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. *American Journal of Clinical Dermatology*, **2021**, 1	7.1	4
341	Unmasking a T cell lymphoma: Folliculotropic mycosis fungoides with a gamma-delta phenotype. *JAAD Case Reports*, **2020**, 6, 1316-1319	1.4	2
340	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. *European Journal of Cancer*, **2020**, 133, 120-130	7.5	11
339	CD209 monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma undergoing extracorporeal photopheresis via the CELLEX system. *Photodermatology Photoimmunology and Photomedicine*, **2020**, 36, 290-298	2.4	2
338	Non-Classic Signs of Sézary Syndrome: A Review. *American Journal of Clinical Dermatology*, **2020**, 21, 383-391	7.1	4
337	Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma **2020**, 1948-1964.e5		
336	Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients. *Archives of Dermatological Research*, **2020**, 312, 283-288	3.3	7

335	Lymphomatoid Papulosis With a Unique T Follicular Helper-Like Phenotype. *American Journal of Dermatopathology*, **2020**, 42, 776-779	0.9	
334	Renal Cell Carcinoma Associated with Mycosis Fungoides: A Paraneoplastic Syndrome. *Case Reports in Nephrology*, **2020**, 2020, 8897183	0.8	0
333	Second primary malignancies in blastic plasmacytoid dendritic cell neoplasm: A national database study. *Journal of the American Academy of Dermatology*, **2020**, 83, 1786-1789	4.5	1
332	United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. *Journal of the American Academy of Dermatology*, **2020**, 83, 703-704	4.5	15
331	Development of Sézary syndrome following the administration of dupilumab. *Dermatology Online Journal*, **2020**, 26,	1	2
330	Anaphylaxis following administration of extracorporeal photopheresis for cutaneous T cell lymphoma. *Dermatology Online Journal*, **2020**, 26,	1	
329	Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. *Radiotherapy and Oncology*, **2019**, 131, 88-92	5.3	3
328	Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15 years later. *International Journal of Dermatology*, **2019**, 58, e221-e222	1.7	2
327	Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. *New England Journal of Medicine*, **2019**, 380, 1628-1637	59.2	173
326	FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL). *Hematological Oncology*, **2019**, 37, 286-288	1.3	1
325	Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. *Journal of Cutaneous Pathology*, **2019**, 46, 872-877	1.7	3
324	Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma. *Oncotarget*, **2019**, 10, 3183-3197	3.3	3
323	RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS FROM FIVE TRIALS IN PTCL, CTCL, AND B-CELL LYMPHOMAS. *Hematological Oncology*, **2019**, 37, 470-471	1.3	2
322	Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. *American Journal of Clinical Dermatology*, **2019**, 20, 115-122	7.1	15
321	Proteomic analysis of stratum corneum in Cutaneous T-Cell Lymphomas and psoriasis. *Experimental Dermatology*, **2019**, 28, 317-321	4	2
320	Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides. *Leukemia and Lymphoma*, **2019**, 60, 1079-1082	1.9	2
319	Primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoproliferative disorder in a pediatric patient successfully treated with low-dose radiation. *Pediatric Dermatology*, **2019**, 36, e23-e26	1.9	1
318	Nail irregularities associated with Sézary syndrome. *Cutis*, **2019**, 103, E11-E16	0.4	2

317	Waistband Mycosis Fungoides: A New Clinical Variant of Early-Stage Disease. *Skinmed*, **2019**, 17, 329-332	0.2	
316	Necrotizing Granulomatous Dermatitis and Panniculitis Masquerading as T Cell Lymphoma. *Skinmed*, **2019**, 17, 406-408	0.2	1
315	Image Gallery: Symmetrical whirled eschars on the face in mycosis fungoides. *British Journal of Dermatology*, **2018**, 178, e224	4	1
314	Childhood alopecia areata-Data from the National Alopecia Areata Registry. *Pediatric Dermatology*, **2018**, 35, 164-169	1.9	12
313	How to Discern Folliculotropic Mycosis Fungoides From Follicular Mucinosis Using a Pediatric Case. *Journal of Cutaneous Medicine and Surgery*, **2018**, 22, 336-340	1.6	11
312	Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia. *Clinical and Experimental Dermatology*, **2018**, 43, 449-453	1.8	2
311	The Utility and Validity of the Alopecia Areata Symptom Impact Scale in Measuring Disease-Related Symptoms and their Effect on Functioning. *Journal of Investigative Dermatology Symposium Proceedings*, **2018**, 19, S41-S46	1.1	10
310	Mycosis fungoides occurring at the site of previous herpes zoster eruption. *Australasian Journal of Dermatology*, **2018**, 59, 217-219	1.3	2
309	Generalized morphea/eosinophilic fasciitis overlap after epoxy exposure. *JAAD Case Reports*, **2018**, 4, 175-178	1.4	2
308	The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. *American Journal of Surgical Pathology*, **2018**, 42, 726-734	6.7	14
307	Important considerations for legislation banning commercial tanning beds among minors. *Clinics in Dermatology*, **2018**, 36, 104-105	3	
306	Differential expression of CCR4 in primary cutaneous gamma/delta (γδ) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. *Journal of Dermatological Science*, **2018**, 89, 88-91	4.3	9
305	Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. *Leukemia and Lymphoma*, **2018**, 59, 880-887	1.9	16
304	Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma. *British Journal of Dermatology*, **2018**, 178, 302-303	4	4
303	Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. *OncoImmunology*, **2018**, 7, e1467856	7.2	16
302	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 1192-1204	21.7	239
301	Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. *British Journal of Haematology*, **2018**, 183, 428-444	4.5	129
300	High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata. *JCI Insight*, **2018**, 3,	9.9	25

299	Juvenile mycosis fungoides with large-cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon-alfa, and localized radiation. *Pediatric Dermatology*, **2018**, 35, e13-e16	1.9	2
298	The "Duvic regimen" for erythrodermic flares secondary to Staphylococcus aureus in mycosis fungoides and S□ary syndrome. *International Journal of Dermatology*, **2018**, 57, 123-124	1.7	8
297	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. *Case Reports in Oncology*, **2018**, 11, 721-728	1	
296	Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T-cell lymphoma. *Journal of the European Academy of Dermatology and Venereology*, **2018**, 32, 1652-1656	4.6	12
295	Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series. *Journal of Dermatological Treatment*, **2017**, 28, 567-569	2.8	13
294	Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. *Clinical Cancer Research*, **2017**, 23, 3552-3556	12.9	19
293	Immunophenotypic Shifts in Primary Cutaneous □T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. *American Journal of Surgical Pathology*, **2017**, 41, 431-445	6.7	10
292	Forodesine in the treatment of cutaneous T-cell lymphoma. *Expert Opinion on Investigational Drugs*, **2017**, 26, 771-775	5.9	5
291	Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. *OncoImmunology*, **2017**, 6, e1306618	7.2	52
290	Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. *Archives of Dermatological Research*, **2017**, 309, 453-459	3.3	22
289	Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (□) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous □T-Cell Lymphomas. *American Journal of Surgical Pathology*, **2017**, 41, 204-215	6.7	41
288	Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. *Advances in Radiation Oncology*, **2017**, 2, 363-369	3.3	5
287	Brentuximab vedotin or physician□s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. *Lancet, The*, **2017**, 390, 555-566	40	303
286	Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides. *Dermatologic Therapy*, **2017**, 30, e12485	2.2	6
285	Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. *JAMA Dermatology*, **2017**, 153, 1302-1306	5.1	20
284	Generalised Eruptive Keratoacanthomas of Grzybowski. *Journal of Cutaneous Medicine and Surgery*, **2017**, 21, 439	1.6	
283	Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report. *Journal of Cutaneous Medicine and Surgery*, **2017**, 21, 568-571	1.6	1
282	BRENTUXIMAB VEDOTIN VS PHYSICIAN□S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. *Hematological Oncology*, **2017**, 35, 77-78	1.3	1

281	Oral bexarotene for post-transplant cutaneous T-cell lymphoma. *Dermatologic Therapy*, **2017**, 30, e12524	2.2	5
280	Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma. *Expert Review of Hematology*, **2017**, 10, 757-760	2.8	4
279	A possible association between mycosis fungoides and Muir-Torre syndrome: Two disorders with microsatellite instability. *JAAD Case Reports*, **2017**, 3, 358-361	1.4	1
278	RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. *Hematological Oncology*, **2017**, 35, 245-247	1.3	1
277	PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. *Hematological Oncology*, **2017**, 35, 247-248	1.3	2
276	An adolescent with granulomatous mycosis fungoides infiltrating skeletal muscle successfully treated with oral prednisone. *JAAD Case Reports*, **2017**, 3, 276-279	1.4	1
275	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. *Journal of Cutaneous Pathology*, **2017**, 44, 158-176	1.7	135
274	Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. *Clinical Cancer Research*, **2017**, 23, 1299-1311	12.9	20
273	Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox. *JAAD Case Reports*, **2017**, 3, 501-504	1.4	11
272	Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 1535-1536	4	4
271	Novel Mutations Involving NF-B and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sary Syndrome. *Journal of Investigative Dermatology*, **2017**, 137, 1831-1833	4.3	5
270	TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform. *Frontiers in Medicine*, **2017**, 4, 153	4.9	12
269	Curcumin for the treatment of tumor-stage mycosis fungoides. *Dermatologic Therapy*, **2017**, 30, e12511	2.2	3
268	ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-B pathways. *Oncotarget*, **2017**, 8, 61761-61776	3.3	16
267	The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. *Cancer Treatment Reviews*, **2016**, 43, 58-66	14.4	40
266	Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma. *Journal of Cutaneous Pathology*, **2016**, 43, 1121-1130	1.7	26
265	Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. *Journal of Cutaneous Pathology*, **2016**, 43, 1161-1166	1.7	29
264	Primkutane CD30(+) lymphoproliferative Erkrankungen. *JDDG - Journal of the German Society of Dermatology*, **2016**, 14, 767-84	1.2	7

263	Mogamulizumab in the treatment of cutaneous T cell lymphoma. *Expert Opinion on Orphan Drugs*, **2016**, 4, 1277-1280	1.1	
262	Granulomatous Mycosis Fungoides in an Adolescent-A Rare Encounter and Review of the Literature. *Pediatric Dermatology*, **2016**, 33, e296-8	1.9	6
261	Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. *Therapeutic Advances in Hematology*, **2016**, 7, 171-4	5.7	26
260	ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. *Cancer Cell*, **2016**, 29, 874-888	24.3	29
259	Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy. *OncoImmunology*, **2016**, 5, e1175799	7.2	22
258	BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. *Human Pathology*, **2016**, 50, 79-89	3.7	16
257	Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. *Journal of the American Academy of Dermatology*, **2016**, 74, 59-67	4.5	81
256	Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 49-56	2	38
255	A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, e15-9	2	12
254	Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study. *Blood*, **2016**, 128, 182-182	2.2	10
253	First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. *Blood*, **2016**, 128, 1826-1826	2.2	3
252	Mycosis Fungoides of the Oral Cavity: Fungating Tumor Successfully Treated with Electron Beam Radiation and Maintenance Bexarotene. *Case Reports in Dermatological Medicine*, **2016**, 2016, 5857935	0.8	7
251	A case of indeterminate dendritic cell tumor presenting with leonine facies. *Journal of Cutaneous Pathology*, **2016**, 43, 158-63	1.7	9
250	Scleromyxedema: long-term follow-up after high-dose melphalan with autologous stem cell transplantation. *International Journal of Dermatology*, **2016**, 55, e539-43	1.7	11
249	Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. *EBioMedicine*, **2016**, 7, 240-7	8.8	51
248	Lymphomatoid Papulosis in Children and Adolescents: A Systematic Review. *American Journal of Clinical Dermatology*, **2016**, 17, 319-27	7.1	30
247	Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 637-643	2	15
246	Primary cutaneous CD30(+) lymphoproliferative disorders. *JDDG - Journal of the German Society of Dermatology*, **2016**, 14, 767-82	1.2	4

245	Cutaneous T-cell lymphoma in a patient with celiac disease. *Cutis*, **2016**, 98, E1-2	0.4	
244	Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 358-363	2	37
243	An unusual case of cytotoxic peripheral T-cell lymphoma. *JAAD Case Reports*, **2015**, 1, 257-60	1.4	4
242	Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. *Cancer*, **2015**, 121, 1993-2003	6.4	34
241	Advanced-stage mycosis fungoides and S□ary syndrome: survival and response to treatment. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, e105-12	2	27
240	Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. *Leukemia and Lymphoma*, **2015**, 56, 2847-54	1.9	13
239	Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. *Human Pathology*, **2015**, 46, 558-69	3.7	29
238	Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma. *Dermatologic Clinics*, **2015**, 33, 757-64	4.2	25
237	Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. *Journal of Clinical Oncology*, **2015**, 33, 3759-65	2.2	203
236	Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. *OncoImmunology*, **2015**, 4, e1011524	7.2	22
235	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S□ary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. *Journal of Clinical Oncology*, **2015**, 33, 3766-73	2.2	237
234	Resimmune, an anti-CD3□recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. *Haematologica*, **2015**, 100, 794-800	6.6	33
233	Leonine facies (LF) and mycosis fungoides (MF): A single-center study and systematic review of the literature. *Journal of the American Academy of Dermatology*, **2015**, 73, 976-86	4.5	20
232	Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. *Annals of Oncology*, **2015**, 26, 2490-5	10.3	63
231	Genomic profiling of S□ary syndrome identifies alterations of key T cell signaling and differentiation genes. *Nature Genetics*, **2015**, 47, 1426-34	36.3	199
230	Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With S□ary Syndrome. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, e83-93	2	30
229	Reed syndrome presenting with leiomyosarcoma. *JAAD Case Reports*, **2015**, 1, 150-2	1.4	13
228	Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and S□ary syndrome. *Hematology American Society of Hematology Education Program*, **2015**, 2015, 529-44	3.1	11

227	Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. *Cancer Medicine*, **2015**, 4, 1440-7	4.8	33
226	Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. *Blood*, **2015**, 125, 1883-9	2.2	165
225	The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma. *Photodermatology Photoimmunology and Photomedicine*, **2015**, 31, 184-94	2.4	14
224	A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. *British Journal of Haematology*, **2015**, 168, 811-9	4.5	131
223	Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. *Journal of the American Academy of Dermatology*, **2015**, 72, 286-92	4.5	117
222	Lymphomatoid Papulosis: Assessing Treatment Response and Associated Lymphomas in a Study of 180 Patients. *Blood*, **2015**, 126, 1487-1487	2.2	
221	Blood Transcriptional Profiling in Patients with Leukemic Cutaneous T-Cell Lymphoma on Extracorporeal Photopheresis Reveals the Integrin Signaling As the Top Pathway Associated with Clinical Response. *Blood*, **2015**, 126, 3981-3981	2.2	
220	Vitamin D deficiency in mycosis fungoides and S□ary syndrome patients is similar to other cancer patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 518-24	2	13
219	T-cell receptor-□n gamma-delta phenotype cutaneous T-cell lymphoma can be accompanied by atypical expression of CD30, CD4, or TCR□1 and an indolent clinical course. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, e195-200	2	13
218	Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: a case series of 34 patients. *Journal of the American Academy of Dermatology*, **2014**, 71, 1117-26	4.5	55
217	Alopecia areata after HLA-identical BMT from an affected, sibling donor. *Bone Marrow Transplantation*, **2014**, 49, 592-4	4.4	4
216	Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series. *American Journal of Clinical Dermatology*, **2014**, 15, 451-6	7.1	2
215	Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 297-304	2	15
214	Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and S□ary syndrome. *Blood*, **2014**, 123, 1159-66	2.2	61
213	Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and S□ary syndrome). *Annals of Oncology*, **2014**, 25, 1807-1812	10.3	32
212	S□ary syndrome: an overview of current and future treatment options. *Expert Opinion on Orphan Drugs*, **2014**, 2, 889-901	1.1	
211	Concurrent chronic lymphocytic leukemia and cutaneous T cell lymphoma: a case series. *Leukemia and Lymphoma*, **2014**, 55, 2192-5	1.9	1
210	Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. *Expert Review of Clinical Pharmacology*, **2014**, 7, 591-7	3.8	14

209	Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. *Cell Cycle*, **2014**, 13, 3331-5	4.7	73
208	A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. *International Journal of Dermatology*, **2013**, 52, 1111-4	1.7	10
207	A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. *European Journal of Cancer*, **2013**, 49, 2859-68	7.5	87
206	Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 377-84	2	29
205	Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and S□ary syndrome. *Leukemia and Lymphoma*, **2013**, 54, 69-75	1.9	19
204	Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. *Leukemia and Lymphoma*, **2013**, 54, 284-9	1.9	34
203	Panobinostat activity in both bexarotene-exposed and -na□e patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. *European Journal of Cancer*, **2013**, 49, 386-94	7.5	104
202	Papuloerythroderma of Ofuji associated with an indolent CD3(-), CD4(+), TCR(-) peripheral T-cell lymphoma. *Leukemia and Lymphoma*, **2013**, 54, 2059-61	1.9	2
201	Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series. *Cancer*, **2013**, 119, 825-31	6.4	34
200	Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. *Leukemia and Lymphoma*, **2013**, 54, 514-9	1.9	12
199	Augmentation of blood dendritic cells by extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma and graft-versus-host disease. *Journal of Investigative Dermatology*, **2013**, 133, 2098-100	4.3	18
198	Primary cutaneous follicle center lymphoma following deep brain stimulation implants. *Leukemia and Lymphoma*, **2013**, 54, 1806-7	1.9	
197	Cutaneous T-Cell Lymphomas: Mycosis Fungoides and S□ary Syndrome **2013**, 287-329		2
196	Cutaneous T-Cell Lymphomas **2013**, 155-177		
195	Increased Twist expression in advanced stage of mycosis fungoides and S□ary syndrome. *Journal of Cutaneous Pathology*, **2012**, 39, 500-7	1.7	23
194	Prevalence and severity of pruritus in cutaneous T cell lymphoma. *International Journal of Dermatology*, **2012**, 51, 930-4	1.7	48
193	Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. *Blood*, **2012**, 119, 4115-22	2.2	104
192	Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. *Photodermatology Photoimmunology and Photomedicine*, **2012**, 28, 250-7	2.4	32

191	HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. *Future Medicinal Chemistry*, **2012**, 4, 471-86	4.1	54
190	Long-term outcomes of 1,263 patients with mycosis fungoides and S□ary syndrome from 1982 to 2009. *Clinical Cancer Research*, **2012**, 18, 5051-60	12.9	188
189	Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/S□ary syndrome receiving placebo. *Journal of the American Academy of Dermatology*, **2012**, 67, 867-75	4.5	13
188	Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas. *Clinical Lymphoma, Myeloma and Leukemia*, **2012**, 12, 180-5	2	12
187	Trends in the treatment of cutaneous T-cell lymphoma – critical evaluation and perspectives on vorinostat. *Blood and Lymphatic Cancer: Targets and Therapy*, **2012**, 17	2.6	1
186	Cutaneous □T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. *American Journal of Surgical Pathology*, **2012**, 36, 1656-65	6.7	119
185	Multicenter photopheresis intervention trial in early-stage mycosis fungoides. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 219-27	2	30
184	Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 286-8	2	12
183	The spectrum of hair loss in patients with mycosis fungoides and S□ary syndrome. *Journal of the American Academy of Dermatology*, **2011**, 64, 53-63	4.5	37
182	S□ary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). *Journal of the American Academy of Dermatology*, **2011**, 64, 352-404	4.5	133
181	CO26. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. *Melanoma Research*, **2011**, 21, e15-e16	3.3	3
180	S□ary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. *Blood*, **2011**, 117, 3382-90	2.2	28
179	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. *Blood*, **2011**, 118, 4024-35	2.2	295
178	CD30+ neoplasms of the skin. *Current Hematologic Malignancy Reports*, **2011**, 6, 245-50	4.4	55
177	Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. *American Journal of Hematology*, **2011**, 86, 627-30	7.1	9
176	Clinical end points and response criteria in mycosis fungoides and S□ary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. *Journal of Clinical Oncology*, **2011**, 29, 2598-607	2.2	407
175	Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL. *Blood*, **2011**, 118, 1638-1638	2.2	2
174	Dendritic cells and cutaneous T-cell lymphomas. *Giornale Italiano Di Dermatologia E Venereologia*, **2011**, 146, 103-13	0.8	8

173	Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy. *Clinical and Experimental Dermatology*, **2010**, 35, 409-16	1.8	50
172	Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. *Nature*, **2010**, 466, 113-7	50.4	500
171	Vorinostat for the treatment of cutaneous T-cell lymphoma. *Expert Review of Dermatology*, **2010**, 5, 393-401		1
170	Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. *Journal of Clinical Oncology*, **2010**, 28, 2365-72	2.2	122
169	Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patientsM PBMCs: potential role for STAT-3 and NF-kappaB signaling. *Journal of Investigative Dermatology*, **2010**, 130, 2110-9	4.3	81
168	Rational clinical trial design in cutaneous lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2010**, 10 Suppl 2, S80-3	2	
167	Treatment of Cutaneous T-cell Lymphomas **2010**, 449-457		
166	Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology* , **2010**, 63, 975-83	4.5	79
165	Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. *Journal of Clinical Oncology*, **2010**, 28, 4485-91	2.2	502
164	HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 6532-7	11.5	129
163	Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. *Journal of Clinical Oncology*, **2010**, 28, 1870-7	2.2	179
162	Primary and metastatic malignant tumors of the scalp: an update. *American Journal of Clinical Dermatology*, **2010**, 11, 233-46	7.1	18
161	A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. *Clinical Cancer Research*, **2009**, 15, 6217-24	12.9	73
160	Detection of high-risk human papillomaviruses in verrucae of patients with mycosis fungoides and Sézary syndrome: a case series. *International Journal of Dermatology*, **2009**, 48, 598-602	1.7	7
159	Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. *International Journal of Dermatology*, **2009**, 48, 243-52	1.7	92
158	Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. *Clinical and Experimental Dermatology*, **2009**, 34, 576-81	1.8	74
157	Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. *Journal of the American Academy of Dermatology*, **2009**, 60, 231-5	4.5	55
156	History of atopy or autoimmunity increases risk of alopecia areata. *Journal of the American Academy of Dermatology*, **2009**, 61, 581-91	4.5	120

155	Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. *Clinical Lymphoma and Myeloma*, **2009**, 9, 412-6		74
154	Efficacy and safety of topical tazarotene: a review. *Expert Opinion on Drug Metabolism and Toxicology*, **2009**, 5, 195-210	5.5	18
153	Molecular and Biological Characteristics of Acquired Vorinostat-Resistant Cutaneous T-Cell Lymphoma Cells.. *Blood*, **2009**, 114, 1732-1732	2.2	
152	Primary Sezary Syndrome Commonly Involves Skin Without Epidermotropism. *Journal of Cutaneous Pathology*, **2008**, 32, 85-85	1.7	
151	Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. *Journal of Investigative Dermatology*, **2008**, 128, 2631-2639	4.3	22
150	Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. *Journal of Investigative Dermatology*, **2008**, 128, 2728-2735	4.3	37
149	Human leukocyte antigen class II alleles are associated with risk of alopecia areata. *Journal of Investigative Dermatology*, **2008**, 128, 240-3	4.3	23
148	Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. *British Journal of Dermatology*, **2008**, 159, 105-12	4	130
147	Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitox. *Clinical Lymphoma and Myeloma*, **2008**, 8, 55-8		16
146	Increased malignancy risk in the cutaneous T-cell lymphoma patient population. *Clinical Lymphoma and Myeloma*, **2008**, 8, 100-5		25
145	Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation. *Journal of the American Academy of Dermatology*, **2008**, 59, S16-22	4.5	18
144	EGFR inhibitor-associated acneiform folliculitis: assessment and management. *American Journal of Clinical Dermatology*, **2008**, 9, 285-94	7.1	23
143	Optimizing denileukin diftitox (Ontak) therapy. *Future Oncology*, **2008**, 4, 457-69	3.6	46
142	Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2008**, 6, 436-42	7.3	97
141	Skin directed therapy for mycosis fungoides: a review. *Journal of Drugs in Dermatology*, **2008**, 7, 655-66	2.2	27
140	Pulmonary manifestations in patients with cutaneous T-cell lymphomas. *Cancer*, **2007**, 109, 1550-5	6.4	15
139	The optimal use of bexarotene in cutaneous T-cell lymphoma. *British Journal of Dermatology*, **2007**, 157, 433-40	4	111
138	Mycosis fungoides: pathophysiology and emerging therapies. *Seminars in Oncology*, **2007**, 34, S21-8	5.5	33

137	Activation of HIV in Human Skin by Ultraviolet B Radiation and its Inhibition by NFB Blocking Agents¶. *Photochemistry and Photobiology*, **2007**, 74, 805-810	3.6	2
136	Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine. *Oncology*, **2007**, 73, 130-5	3.6	8
135	Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. *Journal of Clinical Oncology*, **2007**, 25, 3109-15	2.2	835
134	Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). *Blood*, **2007**, 109, 31-9	2.2	924
133	Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. *Blood*, **2007**, 110, 3015-27	2.2	96
132	Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. *Blood*, **2007**, 109, 4655-62	2.2	168
131	Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). *Blood*, **2007**, 110, 1713-22	2.2	1012
130	Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. *Expert Opinion on Investigational Drugs*, **2007**, 16, 1111-20	5.9	248
129	Coexistent psoriasis and lupus erythematosus treated with alefacept. *American Journal of Clinical Dermatology*, **2007**, 8, 47-50	7.1	6
128	Vorinostat in cutaneous T-cell lymphoma. *Drugs of Today*, **2007**, 43, 585-99	2.5	43
127	Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. *Biologics: Targets and Therapy*, **2007**, 1, 377-92	4.4	27
126	Retinoids in Cutaneous T-Cell Lymphomas. *Basic and Clinical Dermatology*, **2007**, 183-196		1
125	Overall Survival in Erythrodermic Cutaneous T-Cell Lymphoma: An Analysis of Prognostic Factors in a Cohort of Erythrodermic Cutaneous T-Cell Lymphoma Patients.. *Blood*, **2007**, 110, 3574-3574	2.2	
124	Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. *Oncology*, **2007**, 21, 33-40	1.8	8
123	Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 2205-8	5.6	25
122	Photopheresis versus transimmunization?. *Leukemia and Lymphoma*, **2006**, 47, 1449	1.9	2
121	Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene. *Clinical Lymphoma and Myeloma*, **2006**, 6, 488-92		8
120	Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. *Clinical Lymphoma and Myeloma*, **2006**, 7, 51-8		119

119	Mycosis fungoides with coccidioidomycosis. *Clinical Lymphoma and Myeloma*, **2006**, 7, 148-50		5
118	A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. *Journal of the American Academy of Dermatology*, **2006**, 55, 807-13	4.5	52
117	High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma. *Melanoma Research*, **2006**, 16, 461-3	3.3	26
116	Treatment of cutaneous T-cell lymphoma with retinoids. *Dermatologic Therapy*, **2006**, 19, 264-71	2.2	64
115	Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. *British Journal of Cancer*, **2006**, 95, S13-S19	8.7	27
114	CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. *Journal of Investigative Dermatology*, **2006**, 126, 575-83	4.3	87
113	Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.. *Blood*, **2006**, 108, 2467-2467	2.2	10
112	Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial. *Journal of Clinical Oncology*, **2006**, 24, 7500-7500	2.2	19
111	Induction of Polyclonal T-Cell Responses Against Cutaneous T-Cell Lymphomas by Autologous Dendritic Cells Transfected with Amplified Tumor RNA.. *Blood*, **2006**, 108, 5189-5189	2.2	
110	Primary cutaneous B-cell lymphoma. *Journal of the American Academy of Dermatology*, **2005**, 53, 479-84	4.5	46
109	Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. *Journal of Investigative Dermatology*, **2005**, 124, 741-50	4.3	38
108	Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. *Journal of Investigative Dermatology* , **2005**, 125, 1045-52	4.3	198
107	Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. *Clinical Cancer Research*, **2004**, 10, 5587-94	12.9	28
106	Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. *Cancer Research*, **2004**, 64, 7361-9	10.1	84
105	Bone marrow transplantation in Jehovah's Witnesses. *Leukemia and Lymphoma*, **2004**, 45, 635-6	1.9	3
104	The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. *Journal of Investigative Dermatology* , **2004**, 123, 380-7	4.3	24
103	Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. *Cancer*, **2004**, 100, 342-9	6.4	66
102	Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. *Clinical Lymphoma and Myeloma*, **2004**, 5, 190-3		11

101	Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. *Journal of the American Academy of Dermatology*, **2004**, 51, 200-4	4.5	23
100	Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. *Journal of the American Academy of Dermatology*, **2004**, 50, 600-7	4.5	49
99	Cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology*, **2004**, 51, S43-5	4.5	10
98	A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. *Blood*, **2004**, 104, 328-35	2.2	153
97	Extracorporeal Photopheresis for the Treatment of Cutaneous T-Cell Lymphoma. *Journal of Cutaneous Medicine and Surgery*, **2003**, 7, 3-7	1.6	33
96	Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. *Blood*, **2003**, 101, 2132-6	2.2	67
95	Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. *Journal of Cutaneous Medicine and Surgery*, **2003**, 7, 3-7	1.6	25
94	Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. *International Journal of Dermatology*, **2003**, 42, 116-22	1.7	29
93	Long-term control of mycosis fungoides of the hands with topical bexarotene. *International Journal of Dermatology*, **2003**, 42, 238-41	1.7	6
92	Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. *Journal of Investigative Dermatology*, **2003**, 121, 902-9	4.3	33
91	Alopecia areata registry: an overview. *Journal of Investigative Dermatology Symposium Proceedings*, **2003**, 8, 219-21	1.1	18
90	Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. *Dermatologic Therapy*, **2003**, 16, 322-30	2.2	59
89	Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. *Hematology/Oncology Clinics of North America*, **2003**, 17, 1405-19	3.1	30
88	Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology*, **2003**, 49, 35-49	4.5	58
87	Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation : successful treatment using radiation therapy plus oral bexarotene combination therapy. *American Journal of Clinical Dermatology*, **2003**, 4, 429-33	7.1	11
86	003UVB dose and cell cycle conditions influence the outcome of UVB-induced HIV activation. *Photodermatology Photoimmunology and Photomedicine*, **2002**, 18, 104-104	2.4	
85	A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. *BMC Clinical Pathology*, **2002**, 2, 5	3	50
84	Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). *Leukemia and Lymphoma*, **2002**, 43, 121-6	1.9	52

83	Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. *Archives of Dermatology*, **2002**, 138, 325-32		134
82	Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. *Blood*, **2002**, 100, 3369-73	7.3	113
81	Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). *Clinical Lymphoma and Myeloma*, **2002**, 2, 222-8		80
80	Treatment of cutaneous T cell lymphoma: current status and future directions. *American Journal of Clinical Dermatology*, **2002**, 3, 193-215	7.1	54
79	Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. *Journal of the American Academy of Dermatology*, **2002**, 46, 95-106	4.5	374
78	Cold urticaria in a patient with mycosis fungoides. *Journal of the American Academy of Dermatology*, **2002**, 47, 608-10	4.5	4
77	Optimizing bexarotene therapy for cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology*, **2002**, 47, 672-84	4.5	142
76	Increased serum immunoglobulin levels are common in mycosis fungoides and Sézary syndrome. *Journal of the American Academy of Dermatology*, **2002**, 47, 685-91	4.5	12
75	The role for interleukin-12 therapy of cutaneous T cell lymphoma. *Annals of the New York Academy of Sciences*, **2001**, 941, 177-84	6.5	44
74	Persistent atypical lymphocytic hyperplasia following tick bite in a child: report of a case and review of the literature. *Pediatric Dermatology*, **2001**, 18, 481-4	1.9	27
73	Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. *International Journal of Dermatology*, **2001**, 40, 505-11	1.7	21
72	The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. *American Journal of Clinical Pathology*, **2001**, 115, 413-21	1.9	70
71	Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. *American Journal of Clinical Pathology*, **2001**, 115, 885-92	1.9	153
70	The genetics of alopecia areata. *Clinics in Dermatology*, **2001**, 19, 135-9	3	22
69	Cutaneous T-cell lymphoma. New immunomodulators. *Dermatologic Clinics*, **2001**, 19, 737-48	4.2	10
68	Therapy options in cutaneous T-cell lymphoma. *Expert Review of Anticancer Therapy*, **2001**, 1, 403-20	3.5	13
67	Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. *Journal of Clinical Oncology*, **2001**, 19, 2456-71	2.2	562
66	Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. *Journal of Clinical Oncology*, **2001**, 19, 376-88	2.2	534

65	Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. *Archives of Dermatology*, **2001**, 137, 581-93		256
64	Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?. *Clinical Cancer Research*, **2001**, 7, 2682-92	12.9	41
63	Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. *Archives of Dermatology*, **2000**, 136, 1461-9		51
62	Cytokine expression patterns distinguish HIV associated skin diseases. *Experimental Dermatology*, **2000**, 9, 341-50	4	12
61	Alitretinoin. *American Journal of Clinical Dermatology*, **2000**, 1, 315-316	7.1	
60	Emerging new therapies for cutaneous T-cell lymphoma. *Dermatologic Clinics*, **2000**, 18, 147-56	4.2	50
59	Enterococcal eschars in cutaneous T-cell lymphoma tumors: a distinct clinical entity. *Clinical Lymphoma and Myeloma*, **2000**, 1, 141-5		9
58	Treatment of cutaneous T-cell lymphoma from a dermatologist's perspective. *Clinical Lymphoma and Myeloma*, **2000**, 1 Suppl 1, S15-20		6
57	Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. *Clinical Lymphoma and Myeloma*, **2000**, 1 Suppl 1, S51-5		19
56	Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. *Clinical Cancer Research*, **2000**, 6, 3249-59	12.9	52
55	Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. *Journal of Clinical Oncology*, **1999**, 17, 3117-21	2.2	88
54	Alopecia areata in families: association with the HLA locus. *Journal of Investigative Dermatology Symposium Proceedings*, **1999**, 4, 220-3	1.1	67
53	Central hypothyroidism associated with retinoid X receptor-selective ligands. *New England Journal of Medicine*, **1999**, 340, 1075-9	59.2	237
52	Flotillin 2 is distinct from epidermal surface antigen (ESA) and is associated with filopodia formation **1999**, 75, 147-159		25
51	Prognostic factor analysis in mycosis fungoides/Sézary syndrome. *Journal of the American Academy of Dermatology*, **1999**, 40, 914-24	4.5	133
50	Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. *Vaccine Journal*, **1999**, 6, 79-84		48
49	Effectiveness of photopheresis in Sézary syndrome. *Archives of Dermatology*, **1999**, 135, 995-7		24
48	DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. *American Journal of Hematology*, **1998**, 58, 87-90	7.1	52

47	Nerve growth factor in normal and psoriatic skin equivalent models. *Archives of Dermatological Research*, **1998**, 290, 610-4	3.3	4
46	The pathogenesis of psoriasis and the mechanism of action of tazarotene. *Journal of the American Academy of Dermatology*, **1998**, 39, S129-33	4.5	41
45	Alopecia areata and cytomegalovirus infection in twins: genes versus environment?. *Journal of the American Academy of Dermatology*, **1998**, 38, 418-25	4.5	101
44	Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10. *Leukemia and Lymphoma*, **1998**, 29, 315-28	1.9	19
43	Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis. *Blood*, **1998**, 92, 1150-1159	2.2	243
42	Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 14811-5	11.5	132
41	Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. *Blood* , **1998**, 92, 1150-9	2.2	31
40	Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis. *Expert Opinion on Investigational Drugs*, **1997**, 6, 1537-51	5.9	13
39	Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. *Journal of the American Academy of Dermatology*, **1997**, 37, 85-92	4.5	141
38	Follicular mucinosis associated with scarring alopecia, oligoclonal T-cell receptor V beta expansion, and Staphylococcus aureus: when does follicular mucinosis become mycosis fungoides?. *Journal of the American Academy of Dermatology*, **1997**, 37, 828-31	4.5	49
37	Molecular mechanisms of tazarotene action in psoriasis. *Journal of the American Academy of Dermatology*, **1997**, 37, S18-S24	4.5	78
36	Association of Erythrodermic Cutaneous T-Cell Lymphoma, Superantigen-Positive Staphylococcus aureus, and Oligoclonal T-Cell Receptor V Gene Expansion. *Blood*, **1997**, 89, 32-40	2.2	191
35	Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. *Journal of Investigative Dermatology*, **1997**, 109, 91-5	4.3	194
34	The sign of Leser-Tr at. *Medical and Pediatric Oncology*, **1997**, 28, 234-7		5
33	Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. *Blood*, **1997**, 89, 32-40	2.2	61
32	Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas. *Clinical Cancer Research*, **1997**, 3, 169-77	12.9	15
31	Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas. *Leukemia and Lymphoma*, **1996**, 24, 103-10	1.9	9
30	Combined modality therapy for cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology*, **1996**, 34, 1022-9	4.5	80

29	Photopheresis therapy for cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology*, **1996**, 35, 573-9	4.5	120
28	Effects of fibroblast-keratinocyte interactions on the secretion of interleukin-8. *Bulletin of Experimental Biology and Medicine*, **1996**, 121, 167-170	0.8	2
27	Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. *Journal of Investigative Dermatology*, **1996**, 106, 269-74	4.3	96
26	HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. *Journal of Investigative Dermatology*, **1996**, 107, 373-6	4.3	71
25	Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non- Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. *Blood*, **1996**, 88, 1771-1779	2.2	57
24	Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non- Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. *Blood*, **1996**, 88, 1771-1779	2.2	2
23	Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. *Blood*, **1996**, 88, 1771-9	2.2	12
22	Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? [see comments]. *Blood*, **1995**, 86, 651-658	2.2	72
21	Analysis of HLA-D locus alleles in alopecia areata patients and families. *Journal of Investigative Dermatology*, **1995**, 104, 5S-6S	4.3	34
20	Epidermal surface antigen (MS17S1) is highly conserved between mouse and human. *Genomics*, **1995**, 27, 251-8	4.3	12
19	Werner's syndrome. *Dermatologic Clinics*, **1995**, 13, 163-8	4.2	6
18	2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. *Blood*, **1994**, 84, 733-738	2.2	53
17	Keratinocyte transglutaminase expression varies in squamous cell carcinomas. *Journal of Investigative Dermatology*, **1994**, 102, 462-9	4.3	21
16	In vivo fluorescence spectroscopy and imaging of human skin tumours. *Lasers in Medical Science*, **1994**, 9, 191-201	3.1	87
15	Human leukocyte antigen-DQB1*03 alleles are associated with alopecia areata. *Journal of Investigative Dermatology*, **1994**, 103, 758-63	4.3	80
14	High-frequency sonography of the skin. *Journal of the European Academy of Dermatology and Venereology*, **1994**, 3, 47-55	4.6	4
13	Response of psoriasis to a new topical retinoid, AGN 190168. *Journal of the American Academy of Dermatology*, **1994**, 30, 581-90	4.5	112
12	Emergence of leprosy in a patient with mycosis fungoides. *Journal of the American Academy of Dermatology*, **1994**, 30, 313-5	4.5	12

11	2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. *Blood*, **1994**, 84, 733-8	2.2	7
10	Cloning and characterization of a novel epidermal cell surface antigen (ESA). *Journal of Biological Chemistry*, **1994**, 269, 19983-91	5.4	25
9	2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. *Blood*, **1994**, 84, 733-738	2.2	2
8	Cloning and characterization of a novel epidermal cell surface antigen (ESA).. *Journal of Biological Chemistry*, **1994**, 269, 19983-19991	5.4	28
7	The gene for a novel epidermal antigen maps near the neurofibromatosis 1 gene. *Genomics*, **1992**, 14, 369-76	4.3	9
6	Blue rubber bleb nevus syndrome: laser photocoagulation of colonic hemangiomas in a child with microcytic anemia. *Pediatric Dermatology*, **1992**, 9, 91-4	1.9	23
5	HLA-D Locus Associations in Alopecia Areata. *Archives of Dermatology*, **1991**, 127, 64		29
4	The human gene for an epidermal surface antigen (M17S1) is located at 17q11-12. *Genomics*, **1991**, 11, 481-2	4.3	7
3	Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter's syndrome: a disease continuum?. *Arthritis and Rheumatism*, **1990**, 33, 1574-8		94
2	Expression of pemphigus vulgaris antigen in cultured human keratinocytes: effect of inhibitors, tunicamycin, and lectins. *Journal of Investigative Dermatology*, **1988**, 90, 708-15	4.3	10
1	Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. *Journal of Cell Biology*, **1988**, 107, 427-46	7.3	326